ATE291899T1 - Screening-verfahren mit hohem durchsatz (hts) unter verwendung von labormühlen oder microfluidics - Google Patents

Screening-verfahren mit hohem durchsatz (hts) unter verwendung von labormühlen oder microfluidics

Info

Publication number
ATE291899T1
ATE291899T1 AT02756105T AT02756105T ATE291899T1 AT E291899 T1 ATE291899 T1 AT E291899T1 AT 02756105 T AT02756105 T AT 02756105T AT 02756105 T AT02756105 T AT 02756105T AT E291899 T1 ATE291899 T1 AT E291899T1
Authority
AT
Austria
Prior art keywords
hts
particle size
compound
microfluidics
high throughput
Prior art date
Application number
AT02756105T
Other languages
English (en)
Inventor
Marie Lindner
Elaine Merisko-Liversidge
Greta Cary
Original Assignee
Marie Lindner
Elan Pharma Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marie Lindner, Elan Pharma Int Ltd filed Critical Marie Lindner
Application granted granted Critical
Publication of ATE291899T1 publication Critical patent/ATE291899T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT02756105T 2001-06-22 2002-06-24 Screening-verfahren mit hohem durchsatz (hts) unter verwendung von labormühlen oder microfluidics ATE291899T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29973301P 2001-06-22 2001-06-22
US33009301P 2001-10-19 2001-10-19
PCT/US2002/016589 WO2003000228A2 (en) 2001-06-22 2002-06-24 Method for high through put screening using a small scale mill or microfluidics

Publications (1)

Publication Number Publication Date
ATE291899T1 true ATE291899T1 (de) 2005-04-15

Family

ID=26971379

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02756105T ATE291899T1 (de) 2001-06-22 2002-06-24 Screening-verfahren mit hohem durchsatz (hts) unter verwendung von labormühlen oder microfluidics

Country Status (8)

Country Link
US (1) US20030087308A1 (de)
EP (1) EP1401401B1 (de)
JP (1) JP2005504266A (de)
AT (1) ATE291899T1 (de)
AU (1) AU2002322019A1 (de)
CA (1) CA2451161A1 (de)
DE (1) DE60203506T2 (de)
WO (1) WO2003000228A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080102121A1 (en) * 1998-11-02 2008-05-01 Elan Pharma International Limited Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
US7758890B2 (en) 2001-06-23 2010-07-20 Lyotropic Therapeutics, Inc. Treatment using dantrolene
CA2465793A1 (en) * 2001-11-07 2003-05-15 Taffy Williams Methods for vascular imaging using nanoparticulate contrast agents
EP1471887B1 (de) * 2002-02-04 2010-04-21 Elan Pharma International Ltd. Arzneistoffnanopartikel mit lysozym-oberflächenstabilisator
WO2004058216A2 (en) * 2002-12-17 2004-07-15 Elan Pharma International Ltd. Milling microgram quantities of nanoparticulate candidate compounds
AU2004296743B2 (en) * 2003-12-05 2010-08-05 Syngenta Participations Ag Submicron mesotrione compositions
EP1855651A4 (de) * 2005-03-03 2011-06-15 Elan Pharma Int Ltd Nanopartikelzusammensetzungen heterocyclischer amidderivate
US20110064803A1 (en) * 2005-05-10 2011-03-17 Elan Pharma International Limited. Nanoparticulate and controlled release compositions comprising vitamin k2
JP2008540546A (ja) * 2005-05-10 2008-11-20 エラン ファーマ インターナショナル リミテッド ナノ粒子クロピドグレル製剤
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
WO2006133045A1 (en) * 2005-06-03 2006-12-14 Elan Pharma International, Limited Nanoparticulate benidipine compositions
CN101262860A (zh) * 2005-06-03 2008-09-10 伊兰制药国际有限公司 纳米微粒对乙酰氨基酚制剂
EA015102B1 (ru) * 2005-06-03 2011-06-30 Элан Фарма Интернэшнл Лтд. Препараты наночастиц мезилата иматиниба
WO2008073068A1 (en) 2005-06-08 2008-06-19 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising cefditoren
ES2335608T3 (es) * 2005-06-09 2010-03-30 Elan Pharma International Limited Formulaciones de ebistina nanoparticuladas.
MX2007015882A (es) * 2005-06-13 2008-03-04 Elan Pharma Int Ltd Formulaciones en combinacion nanoparticulada de clopidogrel y aspirina.
JP2009500356A (ja) * 2005-07-07 2009-01-08 エラン ファーマ インターナショナル リミテッド ナノ粒子クラリスロマイシン製剤
JP2009507925A (ja) * 2005-09-13 2009-02-26 エラン ファーマ インターナショナル リミテッド ナノ粒子タダラフィル製剤
CA2622758A1 (en) * 2005-09-15 2007-03-29 Elan Pharma International, Limited Nanoparticulate aripiprazole formulations
SG170047A1 (en) * 2006-05-30 2011-04-29 Elan Pharma Int Ltd Nanoparticulate posaconazole formulations
JP2009543797A (ja) * 2006-07-10 2009-12-10 エラン ファーマ インターナショナル，リミティド ナノ粒子ソラフェニブ製剤
AU2007272501A1 (en) * 2006-07-12 2008-01-17 Elan Pharma International Limited Nanoparticulate formulations of modafinil
AU2009225719A1 (en) * 2008-03-21 2009-09-24 Elan Pharma International Limited Compositions for site-specific delivery of imatinib and methods of use
EA201171284A1 (ru) * 2009-04-24 2012-05-30 Айсьютика Пти Лтд. Новая технология изготовления напроксена
CN102438594A (zh) 2009-04-24 2012-05-02 伊休蒂卡有限公司 吲哚美辛的新剂型
EP3167875A1 (de) 2009-05-27 2017-05-17 Alkermes Pharma Ireland Limited Reduktion von flockenartiger aggregation in nanoteilchenförmigen meloxicamzusammensetzungen
WO2011146583A2 (en) 2010-05-19 2011-11-24 Elan Pharma International Limited Nanoparticulate cinacalcet formulations
US9334200B2 (en) * 2013-01-28 2016-05-10 Bfp Management, Llc Fertilizer composition and method for suspending fertilizer in an aqueous solution
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
WO2021110545A1 (en) 2019-12-02 2021-06-10 Merck Patent Gmbh Deposition of nanosuspensions of active pharmaceutical ingredients on carriers

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3614980C1 (de) * 1986-05-02 1993-05-27 Draiswerke Gmbh Regelungseinrichtung fuer eine Ruehrwerksmuehle
US5252459A (en) * 1988-09-23 1993-10-12 Abbott Laboratories Indicator reagents, diagnostic assays and test kits employing organic polymer latex particles
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5552160A (en) * 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
AU642066B2 (en) * 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
AU660852B2 (en) * 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
US5349957A (en) * 1992-12-02 1994-09-27 Sterling Winthrop Inc. Preparation and magnetic properties of very small magnetite-dextran particles
US5346702A (en) * 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5298262A (en) * 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5302401A (en) * 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5340564A (en) * 1992-12-10 1994-08-23 Sterling Winthrop Inc. Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en) * 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en) * 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5326552A (en) * 1992-12-17 1994-07-05 Sterling Winthrop Inc. Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants
US5401492A (en) * 1992-12-17 1995-03-28 Sterling Winthrop, Inc. Water insoluble non-magnetic manganese particles as magnetic resonance contract enhancement agents
US5264610A (en) * 1993-03-29 1993-11-23 Sterling Winthrop Inc. Iodinated aromatic propanedioates
FI964061A0 (fi) * 1994-04-11 1996-10-10 Mount Isa Mines Hiertomylly
US5718388A (en) * 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
TW384224B (en) * 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5593097A (en) * 1994-06-10 1997-01-14 Eastman Kodak Company Micro media mill and method of its use
US5525328A (en) * 1994-06-24 1996-06-11 Nanosystems L.L.C. Nanoparticulate diagnostic diatrizoxy ester X-ray contrast agents for blood pool and lymphatic system imaging
US5587143A (en) * 1994-06-28 1996-12-24 Nanosystems L.L.C. Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5585108A (en) * 1994-12-30 1996-12-17 Nanosystems L.L.C. Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
US5466440A (en) * 1994-12-30 1995-11-14 Eastman Kodak Company Formulations of oral gastrointestinal diagnostic X-ray contrast agents in combination with pharmaceutically acceptable clays
US5628981A (en) * 1994-12-30 1997-05-13 Nano Systems L.L.C. Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents
US5571536A (en) * 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5560931A (en) * 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5622938A (en) * 1995-02-09 1997-04-22 Nano Systems L.L.C. Sugar base surfactant for nanocrystals
US5518738A (en) * 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5593657A (en) * 1995-02-09 1997-01-14 Nanosystems L.L.C. Barium salt formulations stabilized by non-ionic and anionic stabilizers
US5591456A (en) * 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5500204A (en) * 1995-02-10 1996-03-19 Eastman Kodak Company Nanoparticulate diagnostic dimers as x-ray contrast agents for blood pool and lymphatic system imaging
US5573783A (en) * 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5543133A (en) * 1995-02-14 1996-08-06 Nanosystems L.L.C. Process of preparing x-ray contrast compositions containing nanoparticles
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5580579A (en) * 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
JP4484247B2 (ja) * 1995-02-24 2010-06-16 エラン ファーマ インターナショナル，リミティド ナノ粒子分散体を含有するエアロゾル
US5747001A (en) * 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
US5718919A (en) * 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
US5573749A (en) * 1995-03-09 1996-11-12 Nano Systems L.L.C. Nanoparticulate diagnostic mixed carboxylic anhydrides as X-ray contrast agents for blood pool and lymphatic system imaging
US5472683A (en) * 1995-03-09 1995-12-05 Eastman Kodak Company Nanoparticulate diagnostic mixed carbamic anhydrides as X-ray contrast agents for blood pool and lymphatic system imaging
US5643552A (en) * 1995-03-09 1997-07-01 Nanosystems L.L.C. Nanoparticulate diagnostic mixed carbonic anhydrides as x-ray contrast agents for blood pool and lymphatic system imaging
US5521218A (en) * 1995-05-15 1996-05-28 Nanosystems L.L.C. Nanoparticulate iodipamide derivatives for use as x-ray contrast agents
US5573750A (en) * 1995-05-22 1996-11-12 Nanosystems L.L.C. Diagnostic imaging x-ray contrast agents
US5834025A (en) * 1995-09-29 1998-11-10 Nanosystems L.L.C. Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
US5942443A (en) * 1996-06-28 1999-08-24 Caliper Technologies Corporation High throughput screening assay systems in microscale fluidic devices
WO1998035666A1 (en) * 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
US6153225A (en) * 1998-08-13 2000-11-28 Elan Pharma International Limited Injectable formulations of nanoparticulate naproxen
US6165506A (en) * 1998-09-04 2000-12-26 Elan Pharma International Ltd. Solid dose form of nanoparticulate naproxen
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US6270806B1 (en) * 1999-03-03 2001-08-07 Elan Pharma International Limited Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
US6267989B1 (en) * 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
AU5300000A (en) * 1999-06-01 2000-12-18 Elan Pharma International Limited Small-scale mill and method thereof
US6316029B1 (en) * 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form

Also Published As

Publication number Publication date
WO2003000228A3 (en) 2003-12-18
WO2003000228A2 (en) 2003-01-03
CA2451161A1 (en) 2003-01-03
EP1401401A2 (de) 2004-03-31
DE60203506T2 (de) 2006-02-16
US20030087308A1 (en) 2003-05-08
JP2005504266A (ja) 2005-02-10
DE60203506D1 (de) 2005-05-04
AU2002322019A1 (en) 2003-01-08
EP1401401B1 (de) 2005-03-30

Similar Documents

Publication Publication Date Title
DE60203506D1 (de) Screening-verfahren mit hohem durchsatz (hts) unter verwendung von labormühlen oder microfluidics
Al-Agel et al. “Turn-off-on” fluorescence probe based functionalized InP quantum wires for detection of cyanide anions
Mark et al. Bionanofabrication of metallic and semiconductor nanoparticle arrays using S-layer protein lattices with different lateral spacings and geometries
Kumar et al. Extracellular biosynthesis of CdSe quantum dots by the fungus, Fusarium oxysporum
Cao et al. Gold nanomaterials in consumer cosmetics nanoproducts: analyses, characterization, and dermal safety assessment
Zhang et al. Comparison of interactions between human serum albumin and silver nanoparticles of different sizes using spectroscopic methods
Sun et al. Synthesis and photoluminescence of ultra-thin ZnO nanowire/nanotube arrays formed by hydrothermal growth
UA46169C2 (uk) Спосіб захисту виробів, субстратів та інших цінних паперів від підробки (варіанти), спосіб маркування виробів для способу захисту, композиція покриття, матеріал та частинка для їх здійснення
Caballero-Díaz et al. Rapid and simple nanosensor by combination of graphene quantum dots and enzymatic inhibition mechanisms
EP1648381A4 (de) Magnetische nanoteilchen-zusammensetzungen und relevante verfahren
WO2004058216A3 (en) Milling microgram quantities of nanoparticulate candidate compounds
BR0314958A (pt) Composição reativa de fóton múltiplo, artigo e método para fabricar um compósito orgânico-inorgânico
O’Connor et al. Commercialization of cellulose nanocrystal (NCC™) production: a business case focusing on the importance of proactive EHS management
Makama et al. A novel method for the quantification, characterisation and speciation of silver nanoparticles in earthworms exposed in soil
TW200615339A (en) Process for the manufacture of self-binding pigmentary particles, dry or in aqueous suspension or dispersion, containing inorganic matter and binders
Sekar et al. DNA damage and repair following in vitro exposure to two different forms of titanium dioxide nanoparticles on trout erythrocyte
Gade et al. Screening of different species of Phoma for the synthesis of silver nanoparticles
Cárdenas et al. Synthesis of cadmium sulfide nanoparticles by biomass of Fusarium oxysporum f. sp. lycopersici
Ryzhkina et al. Low-concentration aqueous solutions of an amphiphilic calix [4] resorcinarene derivative: Self-organization, physicochemical properties, and biological activity under common and hypoelectromagnetic conditions.
Shiratsu et al. Size dependence of magneto-optical activity in silver nanoparticles with dimensions between 10 and 60 nm studied by MCD spectroscopy
ATE402758T1 (de) Wässrige dispersion und ihre verwendung
Roy et al. Biosynthesis of silver nanoparticles by Aspergillus foetidus: optimization of physicochemical parameters
WO2004068108A3 (en) Extracted polarization intensity differential scattering for particle characterization
Zhou et al. Colloid stability of thymine-functionalized gold nanoparticles
Hamedi et al. Controlled biosynthesis of silver nanoparticles using culture supernatant of filamentous fungus

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties